ALYREF recognizes m5C modifications on LGR4 mRNA through its RNA-binding domain, increasing transcript stability and subsequent activity of Wnt/β-catenin signaling in ovarian cancer cells. This evidence concerns the gene LGR4 and ovarian carcinoma.